Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1,044 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
Colorectal Cancer
Primary: Progression-Free Survival (PFS) — 9.99; 11.60; 7.13; 7.36 months — p== 0.872
Phase 3 N=760 Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Metastatic Colorectal Cancer
Primary: Overall Survival — 196; 151 Days — p=0.005178
Phase 2 N=54 First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
Colorectal Neoplasms
Primary: Objective Response (OR) — 0.4390 Proportion of participants — p=0.36
Phase 2 N=338 Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Neoplasm Metastasis · Colorectal Cancer
Primary: Best Overall Response Rate - Independent Review Committee (IRC) — 45.6; 35.7 percentage of participants — p=0.064
Phase 2 N=376 Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)
Colorectal Cancer
Primary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 10.09; 12.55 months — p=0.0555
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 2 N=50 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus
Colorectal Adenocarcinoma
Primary: Overall Response — 0 percentage of participants
Phase 2 N=198 Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS) — 9.1; 8.7 Months — p=0.2309
Phase 2 N=181 Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Progression Free Survival (PFS) — 6.1; 5.3 Months
Phase 2 N=254 Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Survival (OS) Time — 7.9; 10.3; 9.6 months
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Phase 2 N=154 Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rate — 56.47; 37.93 percentage of participants
Phase 2 N=20 A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…
Phase 2 N=76 METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
Colorectal Cancer Metastatic
Primary: Primary - Progression-free Survival (PFS) — 9.2; 9.2 Months of progression-free survival
Phase 2 N=71 Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 4.731; 0.986 months
Phase 2 N=27 Regorafenib in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability. — 20 Participants
Phase 2 N=32 Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Phase 3 N=691 A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer · Metastatic Colon Cancer
Primary: Overall Survival (OS) — 7.4; 4.8 months — p=< .001
Phase 2 N=77 A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set — 54.5 percentage of participants
Phase 2 N=65 Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
Colorectal Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response [PR, Objective Response Rate (ORR)] — 0.0; 4.8; 0.0 percentage of participants
Phase 3 N=811 Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Colorectal Cancer
Primary: OS in Participants With Left-sided Tumors — 37.85; 34.30 Months
Phase 2 N=120 Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination) — 373.00; 370.00 days — p=0.967
Phase 2 N=42 Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
Phase 2 N=116 Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
Colon Cancer · Colorectal Cancer · Rectal Cancer
Primary: Objective Response Rate at Weeks 17 and 25 — 20; 14; 22; 14 percentage of participants
Phase 1 N=82 MEK and MET Inhibition in Colorectal Cancer
Solid Tumor · Colorectal Cancer
Primary: Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 — 0; 0; 0; 1 Dose Limiting Toxicities (DLTs)
Phase 2 N=21 Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
MSS · RAS-mutant Colorectal Cancer
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1; 2 Participants
Phase 2 N=164 Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
Colorectal Carcinoma
Primary: Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization — 46.4; 47.4 percentage of participants
Phase 2 N=36 Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Phase 2 N=80 A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
Colorectal Cancer
Primary: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor — 48.7; 61.0; 33.3; 51.2 percentage of participants — p=0.2707